Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by B. Culjkovic-Kraljacic
A Phase I Trial of Ribavirin and Low-Dose Cytarabine for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia With Elevated eIF4E
Haematologica
Hematology
Related publications
Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients With Relapsed/Refractory Acute Myeloid Leukemia
Advances in Hematology
Hematology
A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Cytarabine Dose for Acute Myeloid Leukemia
New England Journal of Medicine
Medicine
High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902
Leukemia Research
Cancer Research
Oncology
Hematology
Randomized, Phase IIb Study of Low-Dose Cytarabine and Lintuzumab Versus Low-Dose Cytarabine and Placebo in Older Adults With Untreated Acute Myeloid Leukemia
Haematologica
Hematology
Sorafenib as Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Phase I/Ii Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
